Profil

Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Personál20192020202120222023
Počet zaměstnanců na konci roku----676
Staff turnover in EUR----227 386
Turnover LabelEUREUREUREUREUR
Akcie denominované v EUR20192020202120222023
Počet vydaných akcií (v milionech)13,6413,6515,79208,7320,84
Dividenda na akcii-----
Zisk na akcii bez emise nových akcií-0,02-0,71-0,75-1,24-0,73
Přehled zisků a ztrát v milionech EUR dle IAS/IFRS20192020202120222023
Obrat126,2110,3348,1361,3153,7
Provozní zisk (EBIT)-6,3-64,5-75,2-141,4-83,3
Zisk před zdaněním (EBT)-8,8-75,1-91,9-160,2-105,4
Annual net profit/ loss-1,7-64,4-73,4-143,3-101,4
Rozvaha v milionech EUR IAS/IFRS20192020202120222023
Aktiva
Celková běžná aktiva129,2308,4585,8424,7262,8
Celková fixní aktiva145,0151,4240,2207,9206,6
Celková aktiva274,1459,8826,0632,6469,4
Závazky
Celkové krátkodobé závazky41,3175,9369,0277,4158,9
Celkové dlouhodobé závazky97,7206,5286,5135,4182,3
Oprávky celkem0,42,48,31,31,1
Základní kapitál135,277,4170,6219,8128,2
Celkové závazky274,1459,8826,0632,6469,4
Management:
Thomas Lingelbach
Dipal Patel
Franck Grimaud
Frederic Jacotot
Juan Carlos Jaramillo
Peter Bühler
Petra Pesendorfer
Vincent Dequenne
Představenstvo:
Anne-Marie Graffin
Kathrin Jansen
James Connolly
James Sulat
Maïlys Ferrère
Struktura akcionářů v %:
BlackRock Fund Advisors 1,09
Bpifrance Participations SA /PRIVATE EQUITY/ 6,22
CDC Croissance SA 1,49
Deep Track Capital LP 4,99
Groupe Grimaud La Corbière SA 8,73
Medical Strategy GmbH 1,06
Norges Bank Investment Management 1,03
Pfizer Inc. 6,87
Polar Capital LLP 3,61
The Vanguard Group, Inc. 2,58
Streubesitz 62,32
Adresa: Campus Bio-Ouest, 6, rue Alain Bombard, 44800 Saint-Herblain
T: +33-2-28-07-37-10
F: +
I: http://www.valneva.com
E: info@valneva.com